Perioperative management of patients with schizophrenia

V.V. Myasnikova1, 2, A.E. Muronov2

1 The Academician S.N. Fyodorov ISTC “Eye Microsurgery”, Krasnodar

2 Kuban State Medical University, Krasnodar

For correspondence: Victoria V. Myasnikova — Dr. Sci. Med., head of the department of anesthesiology and resuscitation of the Academician S.N. Fyodorov ISTC “Eye Microsurgery”, Krasnodar; e-mail:

For citation: Myasnikova VV, Muronov AE. Perioperative management of patients with schizophrenia. Alexander Saltanov Intensive Care Herald. 2018;2:24–30.

DOI: 10.21320/1818-474X-2018-2-24-30

This article is a review of publications on clinical research and recommendations for managing patients with schizophrenia in the perioperative period in surgical interventions not associated with psychopathology. An anesthesiologist may face behavioral, cognitive and emotional problems in patients with schizophrenia at all stages of the perioperative period. When anesthetizing such patients, it is necessary to take into account the undesirable side effects of antipsychotics, as well as the risk of their interaction with anesthetics. It is also known that schizophrenia often combines with cardiovascular and endocrine diseases, which further increases the risk of anesthesia. The article gives a description of the main groups of drugs for the treatment of schizophrenia — typical and atypical antipsychotics, a tactic of withdrawal or continuation of their admission during the perioperative period. The problem of neuroleptic malignant syndrome is considered — a potentially lethal complication of therapy with these drugs.

Keywords: schizophrenia, perioperative management, antipsychotics, neuroleptic malignant syndrome

Received: 07.02.2018


  1. Kaye A.D., Liu H., Fox C. et al. Psychiatric and Behavioral Disorders. In: Anesthesia and Uncommon diseases. 6th ed. Fliesher L.A., ed. Philadelphia: Saunders Elsevier, 2012: 444–469.
  2. Федеральные клинические рекомендации по диагностике и лечению шизофрении [проект]. Московский НИИпсихиатрии. 2013. Обсуждение на сайте Российского общества психиатров: [Federal clinical guidelines for diagnosis and treatment of schizophrenia (draft). Moscow Research Institute of Psychiatry. 2013. Discussion on the site of the Russian Society of Psychiatrists — (In Russ)]
  3. Remington G., Fervaha G., Foussias G. et al. Antipsychotic dosing: found in translation. J. Psychiatry Neurosci. 2014; 39(4): 223–231.
  4. Zolezzi M. Medication management during electroconvulsant therapy. Neuropsychiatr. Dis. Treat. 2016; 12: 931–939.
  5. Attri J.P., Bala N., Chatrath V. Psychiatric patient and anaesthesia. Indian J. Anaesth. 2012; 56(1): 8–13.
  6. Huyse F.J., Touw D.J., Strack van Schijndel R.J., et al. Measures for patients taking psychotropic drugs who undergo elective surgery. [Article in Dutch] Ned. Tijdschr. Geneeskd. 2007; 151(6): 353–357.
  7. Desai N., Venkatesh C.R., Kumar S.S. QT prolongation and torsades de pointes with psychotropic agents. Indian J. Psychiatry. 2015; 57(3): 305–308.
  8. Mailman R.B., Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 2010; 16(5): 488–501.
  9. Glassman A.H., Bigger J.T., Jr. Antipsychotic drugs: Prolonged QTc interval, torsade de pointes, and sudden death. Am. J. Psychiatry. 2001; 158: 1774–1782.
  10. Smith F.A., Wittmann C.W., Stern T.A. Medical complications of psychiatric treatment. Crit. Care Clin. 2008; 24: 635–656.
  11. Kailasam V.K., Chima V., Nnamdi U., et al. Risperidone-induced reversible neutropenia. Neuropsychiatr. Dis. Treat. 2017; 13: 1975–1977.
  12. Lim M.H., Park J., Park T.W. A Case with Neutropenia Related with the Use of Various Atypical Antipsychotics. Psychiatry Investig. 2013; 10(4): 428–431.
  13. Kawachi I. Physical and psychological consequence of weight gain. J. Clin. Psychiatry. 1999; 60(Suppl. 21): 5–9.
  14. Baptista T. Body weight gain induced by antipsychotic drugs: Mechanisms and management. Acta Psychiatr. Scand. 1999; 100: 3–16.
  15. Singh M.K., Giles L.L., Nasrallah H.A. Pain insensitivity in schizophrenia: Trait or state marker? J. Psychiatr. Pract. 2006: 90–102.
  16. Gugger J.J. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management.CNS Drugs. 2011; 25(8): 659–671.
  17. Bymaster F.P., Felder C.C., Tzavara E., et al. Muscarinic mechanisms of antipsychotic atypicality. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2003; 27(7): 1125–1143.
  18. Shapiro D.A., Renock S., Arrington E., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003. 28(8): 1400–1411.
  19. OʼKeane V., Meaney A.M. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J. Clin. Psychopharmacol. 2005; 25(1): 26–31.
  20. Katta N., Balla S., Aggarwala K. Clozapine-induced hypersensitivity myocarditis presenting as sudden cardiac death. Autops. Case Rep. 2016; 6(4): 9–13.
  21. Chou P.H., Chu C.S., Lin C.H., et al. Use of atypical antipsychotics and risks of cataract development in patients with schizophrenia: A population-based, nested case-control study. Schizophr. Res. 2016; 174(1–3): 137–143.
  22. Khasawneh F.T., Shankar G.S. Minimizing cardiovascular adverse effects of atypical antipsychotic drugs in patients with schizophrenia. Cardiol. Res. Pract. 2014; 2014: 273060.
  23. Sawada N., Higashi K., Yanagi F., et al. Sudden onset of bronchospasm and persistent hypotension during spinal anesthesia in a patient on long-term psychotropic therapy. Masui. 1997; 46: 1225–1229.
  24. Lanctot K.L., Best T.S., Mittman N., et al. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia. J. Clin. Psychiatry. 1998; 59: 550–561.
  25. Hines R.L., Marschall K.E. Psychiatric disease/substance abuse/drug overdose Stoeltingʼs: Anaesthesia and co-existing diseases. 7thed. ELSEVIER, 2017: 611–633.
  26. Kudoh A., Katagai H., Takazawa T. Effect of preoperative discontinuation of antipsychotics in schizophrenic patients on outcome during and after anesthesia. Eur. J. Anaesth. 2004; 21: 414–416.
  27. Kudoh A. Perioperative management of chronic schizophrenic patients. Anesth. Analg. 2005; 101: 1867–1872.
  28. Kudoh A. Preoperative assessment, preparation and prospect of prognosis in schizophrenic patients. Masui. 2010; 59: 1105–1115.
  29. Руководство по клинической анестезиологии: Пер. с англ. / Под ред. Б.Дж. Полларда. Под общ. ред. Л.В. Колотилова, В.В. Мальцева. М.: МЕДпресс-информ, 2006. [Rukovodstvo po klinicheskoy anesteziologii / Pod red. B.Dzh.Pollarda. Pod obshch. red. L.V. Kolotilova, V.V. Malʼtseva. M.: MEDpress-inform, 2006. (In Russ)]
  30. Amstrong S.C., Cozza K.L. Med-psych drug-drug interactions update. Psychosomatics. 2001; 42: 435–437.
  31. Constance L.S.L., Lansing M.G., Khor F.K., Muniandy R.K. Schizophrenia and anaesthesia. BMJ Case Rep. 2017; pii: bcr-2017-221659.
  32. Morgan G.E., Mikhail M.S., Murray M.J. Anesthesia for patients with neurologic and psychiatric diseases. In: Clinical anaesthesiology. 4th ed. G. Morgan, M.S. Mikhail, M.J. Murray, eds. USA: LANGE International edition, 2008: 647–661.
  33. Katz E., Kluger Y., Ravinovici R., et al. Acute surgical abdominal disease in chronic schizophrenic patients: a unique clinical problem. Isr. J. Med. Sci. 1990; 26: 275–277.
  34. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 1991; 148: 1301–1308.
  35. Buckley N.A., Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf. 2000; 23: 215–228.
  36. Naudin J., Capo C., Giusano B., et al. A differential role for interleukin-6 and tumor necrosis factor in schizophrenia? Schizophr. Res. 1997; 26: 227–233.
  37. Kudoh A., Kudo T., Ishihara H., Matsuki A. Depressed pituitary-adrenal response to surgical stress in chronic schizophrenic patients. Neuropsychobiol. 1997; 36: 112–116.
  38. Donnely J.G., MacLeod A.D. Hypotension associated with clozapine after pulmonary bypass. J. Cardiothorac. Vasc. Anesth. 1999; 13: 597–599.
  39. Boakes A.J., Laurence D.R., Lovel K.W., et al. Adverse reactions to local anaesthetic/vasoconstrictor preparations. Br. Dent. J. 1972; 133: 137–140.
  40. Kudoh A., Ishihara H., Matsuki A. Pituitary-adrenal and parasympathetic function of chronic schizophrenic patients with postoperative ileus or hypotension. Neuropsychobiol. 1999; 39: 125–130.
  41. Kudoh A., Katagai H., Takazawa T. Effect of epidural analgesia on postoperative paralytic ileus in chronic schizophrenia. Reg. Anesth. Pain Med. 2001; 26(5): 456–460.
  42. Molnar G., Fava G.A. Intercurrent medical illness in the schizophrenic patients. In: Principles of medical psychiatry. Stoudemire A., Fogel B.S., eds. Orland: Grune & Stratton Inc, 1987: 451.
  43. O’Keeffe S.T., Devlin J.G. Delirium and the dexamethasone suppression test in the elderly. Neuropsychobiol. 1994; 30: 153–156.
  44. Van der Mast R.C. Pathophysiology of delirium. J. Geriatr. Psychiatry Neurol. 1998; 11: 138–145.
  45. Kudoh A., Takahira Y., Katagai H., et al. Schizophrenic patients who develop postoperative confusion have an increased norepinephrine and cortisol response to surgery, Neuropsychobiology. 2002; 46: 7–12.
  46. Kudoh A., Takahira Y., Katagai H., Takazawa T. Cortisol response to surgery and postoperative confusion in depressed patients under general anesthesia with fentanyl. Neuropsychobiology. 2002; 46(1): 22–26.
  47. Goldman M.B., Robertson G.L., Luchins D.J., et al. Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch. Gen. Psychiatry. 1997; 54: 443–449.
  48. Kramer M.R., Vandijik J., Rosin A.J. Mortality in elderly patients with thermoregulatory failure, Arch. Intern. Med. 1989; 149: 1521–1523.
  49. Young D.M. Risk factors for hypothermia in psychiatric patients. Ann. Clin. Psychiatry. 1996; 8: 93–97.
  50. Kudoh A., Takase H., Takazawa T. Chronic treatment with antipsychotics enhances intraoperative core hypothermia, Anesth. Analg. 2004; 98: 111–115.
  51. Vohra S.B. Convulsions after enfluranein a schizophrenic patients receiving neuroleptics. Can. J. Anaesth. 1994; 41: 420–422.
  52. Kudoh A., Katagai H., Takazawa T. Anesthesia with ketamine, propofol, and fentanyl decreases the frequency of postoperative psychosis emergence and confusion in schizophrenic patients. J.Clin. Anesth. 2002; 14(2): 107–110.
  53. Периоперационное ведение пациентов с сопутствующими заболеваниями: Руководство для врачей: B3 т. / Под ред. И.Б. Заболотских.  Т. 3. 2-е изд., перераб. и доп. М.: Практическая медицина, 2018. [Perioperative management of patients with co-existing diseases. Guidelines for doctors in 3 vol., Ed.: I.B. Zabolotskikh. Vol. 3, 2nd ed. M.: Prakticheskaya meditsina, 2016. (In Russ)]
  54. Ishihara H., Satoh Y., Kudo H., et al. No psychological emergence reactions in schizophrenic surgical patients immediately after propofol, fentanyl, and ketamine intravenous anesthesia. J. Anesth. 1999; 13(1): 17–22.
  55. Bajwa S.J., Jindal R., Kaur J., Singh A. Psychiatric diseases: Need for an increased awareness among the anesthesiologists. J. Anaesthesiol. Clin. Pharmacol. 2011; 27(4): 440–446.
  56. Kaye A.D., Liu H., Fox C. et al. Psychiatric and Behavioral Disorders. In: Fliesher L.A., ed. Anesthesia and Uncommon diseases. 6thed. Philadelphia: Saunders Elsevier, 2012: 444–469.
  57. Shaw A., Matthews E.E. Postoperative neuroleptic malignant syndrome. Anaesthesia. 1995; 50: 246–247.
  58. So P.C. Neuroleptic malignant syndrome induced by droperidol. Hong Kong Med. J. 2001; 7: 101–103.
  59. Gillman P.K. Neuroleptic malignant syndrome: mechanisms, interactions, and causality. Mov. Disord. 2010; 25: 1780–1790.
  60. Bhalla T., Maxey D., Sawardekar A., Tobias J.D. Anesthetic management of a pediatric patient with neuroleptic malignant syndrome. J. Anesth. 2012; 26: 250–253.
  61. Kishimoto S., Nakamura K., Arai T., et al. Postoperative neuroleptic malignant syndrome-like symptoms improved with intravenous diazepam: a case report. J. Anesth. 2013; 27: 768–770.
  62. Ramamoorthy K.G., Downey H., Hawthorne P. Rocuronium and sugammadex: An alternative to succinylcholine for electro convulsive therapy in patients with suspected neuroleptic malignant syndrome. J. Anaesthesiol. Clin. Pharmacol. 2011; 27(3): 380–382.
  63. Agrawal P., Agrawal A., Singh I. Neuroleptic malignant syndrome and anaesthesia: A case report. The Indian Anaesthetists Forum. 2010. Jan.
  64. Периоперационное ведение пациентов с сопутствующими заболеваниями: Руководство для врачей: В 3 т. / Под ред. И.Б. Заболотских. Т. 1. 2-еизд. перераб. и доп. М.: Практическая медицина, 2016. [Perioperative management of patients with co-existing diseases. Guidelines for doctors in 3 vol. Ed.: I.B. Zabolotskikh. Vol. 1. 2nd ed. M.: Prakticheskaya meditsina, 2016. (In Russ)]
  65. Периоперационное ведение пациентов с сопутствующими заболеваниями: Руководство для врачей: В 3 т. / Под ред. И.Б.Заболотских. Т. 2. 2-е изд. перераб. и доп. М.: Практическая медицина, 2016. [Perioperative management of patients with co-existing diseases. Guidelines for doctors in 3 vol. Ed.: I.B. Zabolotskikh. Vol. 2. 2nd ed. M.: Prakticheskaya meditsina, 2016. (In Russ)]
  66. Анестезиология-реаниматология: Клинические рекомендации. Под ред. И.Б. Заболотских, Е.М. Шифмана. М.: ГЭОТАР-Медиа, 2016. [Anesthesiology-reanimatology. Clinical guidelines. Eds.: I.B. Zabloltskikh, E.M. Shifman. M. GEOTAR-Media, 2016. (In Russ)]